BioBigData.Korea

Partnering with the people,

Building Health Data for the Future of Medicine

BioBigData.Korea is a government-led research and development initiative
creating comprehensive BioBigData through public engagement to ensure a healthier Korea.

BioBigData.Korea

Partnering with the people,
Building Health Data for the Future of Medicine

BioBigData.Korea is a government-led research and development initiative creating comprehensive BioBigData through public engagement to ensure a healthier Korea.

Message from the Principal Investigator

Welcome to BioBigData.Korea.

BioBigData.Korea(BIKO) aims to establish a robust R&D infrastructure by securing biospecimens – such as blood, urine, and tissue – based on informed consent, integrating clinical, genomic, personally generated health data, and data by public institutions.

This initiative collects samples, clinical information, public data, and health information from a wide range of participants, including patients with rare or severe disease, and the general public. Through advanced methodology, such as genomic analyses, we establish comprehensive Databank and Biobank. The accumulated BioBigData is accessible to researchers via the BioBigData Platform.

By securing integrated BioBigData as a national strategic asset, the initiative will enhance public health standards and drive the development of new drugs and medical devices. It will also enable disease prevention, prediction, and early treatment, playing a pivotal role in building a society where all citizens can live healthier and longer lives.

Your supports are greatly valued as we strive to deliver a healthier Korea.

Thank you.

BioBigData.Korea

Principal Investigator

Director's Signature

Governance Structure

This cross-ministerial initiative led by the Ministry of Health and Welfare(MOHW), the Ministry of Science and ICT(MSIT), the Ministry of Trade, Industry and Resources(MOTIR), and the Korea Disease Control and Prevention Agency(KDCA). The BioBigData.Korea (hereinafter referred to as BIKO) under the KHIDI is responsible for overseeing and ensuring the implementation of the project.

BIKO is a composed of a Secretariat, a Databank, and a Biobank. The Secretariat oversees the overall operation and management of the project. The Databank and Biobank function as human biological material banks and are responsible for the integrated management of BioBigData, including its collection, generation, and provision. The Databank integrates all collected and generated data and verifies that the data can be provided and utilized for research. The Biobank manages human biological materials derived from biospecimens, along wit related information, to ensure their appropriate use in research.

Governance Structure Diagram

Vision & Mission

To establish a national R&D infrastructure by securing 1M participant BioBigData through informed consent, and integrating clinical,
genomic, and public data with personal information for precision medicine and industrial innovation.

Vision and Mission Indicators
Phase One - 5 years
2024 ~ 2028
Clinical and public data of 772,000 people
General Population 585,000
Severe disease Patients 140,000
Rare disease Patients 47,000
Phase Two - 4 years
2029 ~ 2032
Accumulated 1 Million
General Population 710,000
Severe disease Patients 220,000
Rare disease Patients 70,000

Project Flow

Project Flow Diagram

Expected Effect

Set-up icon
Set-up

Demonstrate customized medicine

Provides participants with integrated data analysis results to enable simultaneous prevention, diagnosis, and treatment.

Post-setup icon
Post-setup

Provide R&D infrastructure

Enables research, medical, industrial, and policy applications through the establishment of an integrated bio big data platform

Research applications

AS-IS
  • Reliance of overseas data and foreign subject
  • Time and cost inefficiencies due to fragment of data collection
TO-BE
  • Provision of clinical and genomic data of Koreans
  • Reduce research cost through customized databank access

Medical applications

AS-IS
  • Reliance on empirical and intuitive medicine
TO-BE
  • Realization of data-driven healthcare

Industrial applications

AS-IS
  • Limited AI based diagnostics solution utilizing bigdata
  • Insufficient bigdata for accelerated new drug development
  • Data scarcity for developing healthcare management service and other applications
TO-BE
  • Development of medical diagnostic support systems
  • Big data-based clinical trial design for new drugs
  • Advancement of health management services, etc.

Policy applications

AS-IS
  • Insufficient bigdata analysis of policy environment assessment
TO-BE
  • Understanding public health crises and identification of response tactics, i.e., COVID-19
Standardization icon
Standardization-Driven Cost Savings

Lead bio data standardization

BIKO spearheads biodata standardization using resources of 1M participants.
Adhering to BIKO's guidelines in R&D projects can reduce data collection and utilization costs. Furthermore, integrating biodata across individual projects will expand and accumulate standardized data resources, creating synergies that strengthen the national research infrastructure.